Latigo Biotherapeutics is a clinical-stage biotechnology company that develops novel, non-opioid therapies for chronic pain.
Latigo Biotherapeutics has raised $150.0M in total funding. The most recent round was Series B. The last funding was announced in March 2025.
Latigo Biotherapeutics's investors include Cormorant Asset Management, Blue Owl, Foresite Capital, Westlake Village BioPartners, Sanofi Ventures.
Latigo Biotherapeutics is headquartered in Thousand Oaks, United States.
Latigo Biotherapeutics is a clinical-stage biotechnology company that develops novel, non-opioid therapies for chronic pain.
Latigo Biotherapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Latigo Biotherapeutics — Funding & Investors." VCBacked, March 17, 2025, https://www.vcbacked.co/company/latigo-biotherapeutics. Accessed July 19, 2026.
VCBacked. (2025). Latigo Biotherapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/latigo-biotherapeutics
{{cite web |title=Latigo Biotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/latigo-biotherapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated